Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1761 - 1768 of 12007 results

US Law Firm Mintz Launches In Canada With Toronto Office
March 20, 2023| News

FDA Modernizes Mammography Regulations, Provides Facilities with Eighteen-Month Compliance Deadline
March 20, 2023| Blog| Viewpoint

50 Years In, Industry Has Knives Out For Potent Kickback Law
March 18, 2023| News

Energy & Sustainability Event Highlights — March 2023
March 17, 2023| Article| Viewpoint

DOJ Antitrust Division Announces Indictment Against Health Care Staffing Executive For Nurse Wage-Fixing
March 16, 2023| Blog| Viewpoint

With Diversified Practices And Rising Headcount, Mintz Up 5% In Revenue
March 16, 2023| News

Further Guidance on SVB Provided by the FDIC
March 14, 2023| Alert| Viewpoint

2023’s Largest Health Data Breach So Far Brings Legal Flurry
March 14, 2023| News
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
